Abstract: PO1296
Healthcare Resource Utilization by Patients with Alport Syndrome in the United States: A Retrospective Claims Analysis
Session Information
- Genetic Diseases of the Kidneys: Non-Cystic - I
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Genetic Diseases of the Kidneys
- 1002 Genetic Diseases of the Kidneys: Non-Cystic
Authors
- Deniz, Baris, Reata Pharmaceuticals Inc, Plano, Texas, United States
- Gattu, Sureka, Reata Pharmaceuticals Inc, Plano, Texas, United States
- Mehra, Mohit, Trinity Partners LLC, Waltham, Massachusetts, United States
- Li, Justin W., Trinity Partners LLC, Waltham, Massachusetts, United States
- Yuan, Angela, Trinity Partners LLC, Waltham, Massachusetts, United States
- Khan, Samina, Reata Pharmaceuticals Inc, Plano, Texas, United States
Background
Alport syndrome (AS) is a rare and serious inherited form of chronic kidney disease (CKD) affecting as many as 60,000 persons in the US. In severe cases, patients develop end-stage kidney disease (ESKD) in their 20’s. The health and economic burden associated with AS has not been well- characterized in the literature. This study aims to address this evidence gap.
Methods
A retrospective claims analysis (IBM MarketScan® Commercial Database) was conducted to assess the healthcare resource utilization (HCRU) by patients with AS in the US. Patients enrolled in a health plan for a minimum of six continuous months with at least 1 inpatient or 2 outpatient claims with the AS-specific ICD-10 code were considered to have a diagnosis of AS. Patients with AS were further segmented into CKD stages, where such information was available, to understand the impact of disease progression on HCRU. Patients with AS were age- and gender- matched to a comparator group without AS diagnosis in a 1:5 proportion. The analysis included commercial (medical and pharmacy) claims from 2015 to 2019.
Results
851 patients with AS were identified, of which 518 also had a CKD diagnosis. The mean age was 33.3 years and 51% were males. 16.2% of patients were < 18 years old. Patients with AS required more healthcare services than the matched comparator group. 19.2% of patients with AS and CKD had at least 1 inpatient admission over the course of 6 months, versus 2.1% in the matched cohort; 100% had an outpatient or office visit, versus 61% in the matched cohort; and 26.7% had at least one emergency department visit, versus 6.6% in the matched cohort. The rate of HCRU increased with the increasing CKD stage, the highest utilization being observed in patients with advanced CKD. Approximately 25% of patients with AS were prescribed RAASi’s, which is a commonly used treatment in eligible patients with AS.
Conclusion
Patients with AS were observed to utilize inpatient, outpatient, and emergency department services at higher rates than the comparator group, with high utilization largely driven by late-stage CKD. Consequently, delaying or preventing kidney disease may substantially reduce healthcare expenditures among patients with AS, particularly among patients with ESKD.
Funding
- Commercial Support –